Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AWAWU E IGBINADOLOR

Allopathic & Osteopathic Physicians Internal Medicine Adolescent Medicine

NPI
1386658128
CMS profile
334690
Location
MONROE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,264.02

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,528.15 7
Food and Beverage $735.87 7

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Alnylam Pharmaceuticals Inc. $2,070.10 7
Novartis Pharmaceuticals Corporation $1,054.59 5
Amgen Inc. $125.00 1
AstraZeneca Pharmaceuticals LP $14.33 1

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AWAWU E IGBINADOLOR

NPI 1386658128 · CMS profile ID 334690

Allopathic & Osteopathic Physicians / Internal Medicine / Adolescent Medicine

MONROE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386658128?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386658128?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386658128?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1386658128?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $3,264.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $235.6909/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785835 CMS
Novartis Pharmaceuticals Corporation $526.1309/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785837 CMS
Novartis Pharmaceuticals Corporation $9.0909/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785839 CMS
Novartis Pharmaceuticals Corporation $111.1509/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785843 CMS
Novartis Pharmaceuticals Corporation $172.5309/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086785841 CMS
Alnylam Pharmaceuticals Inc. $371.7404/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853427 CMS
Alnylam Pharmaceuticals Inc. $151.9704/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853431 CMS
Alnylam Pharmaceuticals Inc. $82.8604/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853433 CMS
Alnylam Pharmaceuticals Inc. $105.0004/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853435 CMS
Alnylam Pharmaceuticals Inc. $125.0004/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853437 CMS
Alnylam Pharmaceuticals Inc. $1,081.5604/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853425 CMS
Alnylam Pharmaceuticals Inc. $151.9704/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125853429 CMS
AstraZeneca Pharmaceuticals LP $14.3301/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104408293 CMS
Amgen Inc. $125.0001/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111604726 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $825.59 19
PY2020 $250.77 11
PY2021 $613.59 23
PY2022 $635.48 38
PY2023 $1,376.29 8
PY2024 $3,264.02 14
PY2025 $15.40 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,807,545.77 332
PY2024 Recipient $24,803.18 2
PY2024 Principal investigator $5,575,092.65 467
PY2023 Recipient $5,441.70 12
PY2023 Principal investigator $4,002,304.15 759
PY2022 Recipient $99,385.00 2
PY2022 Principal investigator $3,185,482.26 500
PY2021 Recipient $421,014.16 3
PY2021 Principal investigator $3,556,229.85 34
PY2020 Recipient $145,488.66 2
PY2019 Principal investigator $9,471.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Adamis Pharmaceuticals Corporation $480.00 12/30/2021 Non-covered Recipient Entity
Monroe Biomedical Research
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 843315433
Principal investigator 1 Eli Lilly and Company $6.01 12/16/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819460201
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $216.75 12/16/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 806259019
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,164.20 12/09/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 806259009
Principal investigator 1 PFIZER INC. $4,236.80 12/07/2021 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832536014
Principal investigator 1 PFIZER INC. $2,649.60 11/30/2021 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832631207
Principal investigator 1 PFIZER INC. $915.20 11/30/2021 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832784469
Principal investigator 1 PFIZER INC. $1,920.00 11/30/2021 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832811281
Principal investigator 1 Adamis Pharmaceuticals Corporation $385.00 11/29/2021 Non-covered Recipient Entity
Monroe Biomedical Research
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 843315413
Principal investigator 1 Adamis Pharmaceuticals Corporation $135.00 11/22/2021 Non-covered Recipient Entity
Monroe Biomedical Research
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 843315391
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,894.65 11/18/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 806259021
Principal investigator 1 PFIZER INC. $4,523.20 11/16/2021 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832631197
Principal investigator 1 PFIZER INC. $6,131.20 11/16/2021 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832735457
Principal investigator 1 PFIZER INC. $5,305.60 11/16/2021 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832779369
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,444.15 11/11/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH LLC
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma No dispute reported 06/30/2026 806259011
Principal investigator 1 PFIZER INC. $4,523.20 11/09/2021 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832631187
Principal investigator 1 PFIZER INC. $915.20 11/09/2021 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832786959
Principal investigator 1 PFIZER INC. $11,168.00 11/09/2021 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832797385
Principal investigator 1 PFIZER INC. $16,000.00 11/02/2021 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832631177
Principal investigator 1 PFIZER INC. $19,948.80 10/29/2021 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832861607
Principal investigator 1 PFIZER INC. $10,000.00 10/26/2021 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832839091
Principal investigator 1 PFIZER INC. $103,596.80 10/26/2021 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832872685
Principal investigator 1 Adamis Pharmaceuticals Corporation $135.00 10/05/2021 Non-covered Recipient Entity
Monroe Biomedical Research
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 843315357
Principal investigator 1 Adamis Pharmaceuticals Corporation $1,200.00 09/27/2021 Non-covered Recipient Entity
Monroe Biomedical Research
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients No dispute reported 06/30/2026 843315347
Principal investigator 1 PFIZER INC. $113.80 09/20/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832604043
Principal investigator 1 PFIZER INC. $920.00 09/20/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832604053
Principal investigator 1 Partner Therapeutics, Inc. $1,040.00 09/16/2021 Non-covered Recipient Entity
Monroe Biomedical Research
SCOPE No dispute reported 06/30/2026 809804569
Principal investigator 1 Partner Therapeutics, Inc. $2,023.46 09/01/2021 Non-covered Recipient Entity
Monroe Biomedical Research
SCOPE No dispute reported 06/30/2026 809804485
Principal investigator 1 PFIZER INC. $917.00 07/14/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832920419
Principal investigator 1 Novartis Pharmaceuticals Corporation $409,606.00 06/23/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ENSOVIBEP (MP0420) IN AMBULATORY ADULT PATIENTS WITH SYMPTOMATIC COVID-19 (THE EMPATHY TRIAL) No dispute reported 06/30/2026 800636869
Principal investigator 1 Eli Lilly and Company $51,637.75 01/26/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 819460063
Principal investigator 1 Eli Lilly and Company $768,999.00 01/25/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 819462825
Principal investigator 1 Eli Lilly and Company $178,810.41 01/21/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 819461397
Principal investigator 1 Eli Lilly and Company $1,938,268.07 01/19/2021 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 819464293
Recipient Eli Lilly and Company $22,722.00 01/11/2021 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 819444363
Recipient Eli Lilly and Company $194,141.00 01/05/2021 Covered Recipient Physician A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 819443431
Recipient Eli Lilly and Company $204,151.16 01/04/2021 Covered Recipient Physician A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 819443477